NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.54 -0.02 (-3.57 %)
(As of 05/23/2018 12:39 PM ET)
Previous Close$0.55
Today's Range$0.53 - $0.57
52-Week Range$0.43 - $3.06
Volume2,481 shs
Average Volume234,907 shs
Market Capitalization$96.67 million
P/E RatioN/A
Dividend YieldN/A
Beta0.39

About Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma logoMatinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in the United States. It develops orally delivered therapeutics based on cochleate delivery technology, a proprietary lipid-based drug delivery platform. The company's lead product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B, a broad spectrum anti-fungal drug, which has completed Phase II clinical study for the treatment of fungal infections. Its lead product candidate also includes MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:MTNB
CUSIPN/A
Phone+1-908-4431860

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-7,558.92%
Return on Equity-195.09%
Return on Assets-79.34%

Miscellaneous

EmployeesN/A
Outstanding Shares93,480,000

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The business earned $0.03 million during the quarter. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. View Matinas BioPharma's Earnings History.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Matinas BioPharma.

What price target have analysts set for MTNB?

2 brokerages have issued 1-year target prices for Matinas BioPharma's shares. Their predictions range from $4.00 to $9.00. On average, they anticipate Matinas BioPharma's share price to reach $6.50 in the next twelve months. View Analyst Ratings for Matinas BioPharma.

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a increase in short interest in April. As of April 30th, there was short interest totalling 1,596,278 shares, an increase of 2.3% from the April 13th total of 1,560,924 shares. Based on an average trading volume of 295,583 shares, the short-interest ratio is presently 5.4 days. Approximately 2.2% of the shares of the company are sold short.

Who are some of Matinas BioPharma's key competitors?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the folowing people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 44)
  • Mr. Dominick M. DiPaolo, Sr. VP of Quality & Regulatory Compliance (Age 42)
  • Mr. Gary Gaglione CPA, VP of Fin. & Accounting and Acting CFO (Age 65)
  • Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 71)

Has Matinas BioPharma been receiving favorable news coverage?

Headlines about MTNB stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Matinas BioPharma earned a daily sentiment score of 0.14 on Accern's scale. They also gave media coverage about the company an impact score of 45.98 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Royal Bank of Canada (0.84%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.

Which major investors are buying Matinas BioPharma stock?

MTNB stock was acquired by a variety of institutional investors in the last quarter, including Royal Bank of Canada. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.54.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $96.67 million.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.


MarketBeat Community Rating for Matinas BioPharma (MTNB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Matinas BioPharma (NYSEAMERICAN:MTNB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Matinas BioPharma in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 1,103.70%. The high price target for MTNB is $9.00 and the low price target for MTNB is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.50$6.50$7.6667$7.6667
Price Target Upside: 1,103.70% upside855.88% upside463.73% upside463.73% upside

Matinas BioPharma (NYSEAMERICAN:MTNB) Consensus Price Target History

Price Target History for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN:MTNB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/10/2018Maxim GroupSet Price TargetBuy$4.00View Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$9.00View Rating Details
3/28/2017AegisReiterated RatingBuy ➝ Positive$8.00View Rating Details
(Data available from 5/23/2016 forward)

Earnings

Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings History and Estimates Chart

Earnings by Quarter for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN MTNB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.04)N/AView Earnings Details
5/10/2018Q1 2018($0.04)($0.05)$0.03 millionViewListenView Earnings Details
3/26/2018Q4 2017($0.03)$0.05 millionViewN/AView Earnings Details
11/15/2017Q3 2017($0.05)($0.04)$0.05 million$0.05 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.04)$0.02 million$0.05 millionViewListenView Earnings Details
5/16/2017Q1 2017($0.0350)($0.25)$0.02 millionViewN/AView Earnings Details
4/3/2017Q4 2016($0.08)($0.03)ViewListenView Earnings Details
11/15/2016Q3 2016($0.11)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.03)ViewN/AView Earnings Details
5/13/2016Q1 2016($0.04)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.03)ViewN/AView Earnings Details
11/10/2015Q3 2016($0.03)($0.11)$0.10 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.05)($0.04)$0.10 million$0.08 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.08)($0.07)$0.06 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Matinas BioPharma (NYSEAMERICAN:MTNB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trading and Institutional Ownership History

Insider Trading History for Matinas BioPharma (NYSEAMERICAN:MTNB)
Institutional Ownership by Quarter for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/8/2017Adam K SternDirectorBuy100,000$1.38$138,000.00793,992View SEC Filing  
9/8/2017Roelof RongenCEOBuy5,000$1.36$6,800.003,539,416View SEC Filing  
9/7/2017James S ScibettaDirectorBuy5,000$1.29$6,450.00418,309View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Matinas BioPharma (NYSEAMERICAN MTNB) News Headlines

Source:
DateHeadline
Matinas Biopharma Holdings (MTNB) CEO Jerry Jabbour on Q1 2018 Results - Earnings Call TranscriptMatinas Biopharma Holdings' (MTNB) CEO Jerry Jabbour on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 6:39 PM
Matinas BioPharma (MTNB) Issues Quarterly  Earnings ResultsMatinas BioPharma (MTNB) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 5:57 PM
Matinas BioPharma (MTNB) PT Set at $4.00 by Maxim GroupMatinas BioPharma (MTNB) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - May 10 at 3:23 PM
Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate UpdateMatinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 8:18 AM
Matinas BioPharma Holdings (MTNB) Short Interest UpdateMatinas BioPharma Holdings (MTNB) Short Interest Update
www.americanbankingnews.com - May 9 at 5:24 PM
Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious DiseaseMatinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease
finance.yahoo.com - April 19 at 8:11 AM
Short Interest in Matinas BioPharma Holdings (MTNB) Increases By 7.5%Short Interest in Matinas BioPharma Holdings (MTNB) Increases By 7.5%
www.americanbankingnews.com - April 10 at 6:35 PM
Matinas BioPharma Holdings Inc (MTNB) Short Interest Down 5.4% in MarchMatinas BioPharma Holdings Inc (MTNB) Short Interest Down 5.4% in March
www.americanbankingnews.com - March 27 at 1:27 AM
Matinas BioPharma Reports 2017 Financial ResultsMatinas BioPharma Reports 2017 Financial Results
finance.yahoo.com - March 26 at 5:23 PM
Matinas BioPharma (MTNB) Scheduled to Post Quarterly Earnings on MondayMatinas BioPharma (MTNB) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - March 26 at 1:28 AM
Matinas Biopharma Holdings (MTNB) CEO Jerome Jabbour on Q4 2017 Results - Earnings Call TranscriptMatinas Biopharma Holdings' (MTNB) CEO Jerome Jabbour on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 19 at 5:21 PM
Maxim Group Reiterates $6.00 Price Target for Matinas BioPharma (MTNB)Maxim Group Reiterates $6.00 Price Target for Matinas BioPharma (MTNB)
www.americanbankingnews.com - March 19 at 1:18 PM
Matinas BioPharma Holdings, Inc. to Host Earnings CallMatinas BioPharma Holdings, Inc. to Host Earnings Call
finance.yahoo.com - March 19 at 8:16 AM
Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate UpdateMatinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update
finance.yahoo.com - March 16 at 6:33 PM
Matinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare ConferenceMatinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 15 at 8:11 AM
Matinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and WebcastMatinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast
finance.yahoo.com - March 12 at 8:35 AM
Matinas BioPharma Holdings Inc (MTNB) Sees Large Growth in Short InterestMatinas BioPharma Holdings Inc (MTNB) Sees Large Growth in Short Interest
www.americanbankingnews.com - March 9 at 6:04 PM
Short Interest in Matinas BioPharma Holdings Inc (MTNB) Expands By 7.5%Short Interest in Matinas BioPharma Holdings Inc (MTNB) Expands By 7.5%
www.americanbankingnews.com - March 1 at 3:06 AM
Matinas BioPharma Holdings Inc (MTNB) Short Interest Down 8.0% in JanuaryMatinas BioPharma Holdings Inc (MTNB) Short Interest Down 8.0% in January
www.americanbankingnews.com - February 9 at 6:54 PM
Matinas BioPharma Holdings Inc (MTNB) Short Interest Down 9.1% in JanuaryMatinas BioPharma Holdings Inc (MTNB) Short Interest Down 9.1% in January
www.americanbankingnews.com - January 25 at 1:32 AM
Matinas BioPharma Holdings Inc (MTNB) Sees Large Decline in Short InterestMatinas BioPharma Holdings Inc (MTNB) Sees Large Decline in Short Interest
www.americanbankingnews.com - January 11 at 1:24 AM
Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered ... - GlobeNewswire (press release)Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered ... - GlobeNewswire (press release)
globenewswire.com - January 9 at 8:58 AM
Pre-Open Movers 01/08: (ALDR) (STX) (VUZI) Higher; (AXON) (GPRO) (APPN) Lower (more...)Pre-Open Movers 01/08: (ALDR) (STX) (VUZI) Higher; (AXON) (GPRO) (APPN) Lower (more...)
www.streetinsider.com - January 8 at 5:02 PM
ETF Preview: ETFs, Futures Lower Ahead of Speeches from Fed Officials, Consumer Credit DataETF Preview: ETFs, Futures Lower Ahead of Speeches from Fed Officials, Consumer Credit Data
www.nasdaq.com - January 8 at 10:09 AM
Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous CandidiasisMatinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
finance.yahoo.com - January 8 at 10:09 AM
Short Interest in Matinas BioPharma Holdings Inc (MTNB) Declines By 8.0%Short Interest in Matinas BioPharma Holdings Inc (MTNB) Declines By 8.0%
www.americanbankingnews.com - December 28 at 2:09 AM
Matinas BioPharma (MTNB) Appoints Matthew A. Wikler to Board - StreetInsider.comMatinas BioPharma (MTNB) Appoints Matthew A. Wikler to Board - StreetInsider.com
www.streetinsider.com - December 14 at 8:55 AM
Matinas BioPharma Holdings Inc (MTNB) Short Interest Down 6.2% in NovemberMatinas BioPharma Holdings Inc (MTNB) Short Interest Down 6.2% in November
www.americanbankingnews.com - December 12 at 2:26 AM
Short Interest in Matinas BioPharma Holdings Inc (MTNB) Drops By 2.8%Short Interest in Matinas BioPharma Holdings Inc (MTNB) Drops By 2.8%
www.americanbankingnews.com - November 27 at 9:30 PM
Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate UpdateMatinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 18 at 5:48 AM
Matinas BioPharma Holdings Inc (MTNB) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSMatinas BioPharma Holdings Inc (MTNB) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 17 at 8:21 PM

SEC Filings

Matinas BioPharma (NYSEAMERICAN:MTNB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Matinas BioPharma (NYSEAMERICAN MTNB) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.